Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice
Abstract Background Alzheimer disease (AD) is characterized by the accumulation of beta-amyloid (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline. Current therapeutic approaches have primarily aimed to reduce...
Main Authors: | Hayk Davtyan, Armine Hovakimyan, Sepideh Kiani Shabestari, Tatevik Antonyan, Morgan A. Coburn, Karen Zagorski, Gor Chailyan, Irina Petrushina, Olga Svystun, Emma Danhash, Nikolai Petrovsky, David H. Cribbs, Michael G. Agadjanyan, Mathew Blurton-Jones, Anahit Ghochikyan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13195-019-0556-2 |
Similar Items
-
Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological α-Synuclein
by: Karen Zagorski, et al.
Published: (2022-05-01) -
Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates
by: Armine Hovakimyan, et al.
Published: (2022-10-01) -
Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies
by: Changyoun Kim, et al.
Published: (2022-01-01) -
Author Correction: Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies
by: Changyoun Kim, et al.
Published: (2023-07-01) -
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
by: Michael G. Agadjanyan, et al.
Published: (2017-05-01)